<DOC>
	<DOCNO>NCT00006216</DOCNO>
	<brief_summary>RATIONALE : Ganciclovir may ease side effect cancer treatment . Vaccines make person 's modify malignant mesothelioma cell may make cancer sensitive ganciclovir . PURPOSE : Phase I trial study effectiveness vaccine therapy plus ganciclovir treating patient stage I , stage II , stage III malignant mesothelioma .</brief_summary>
	<brief_title>Vaccine Therapy Ganciclovir Treating Patients With Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety side effect intrapleurally administer PA-1-STK modify ovarian carcinoma vaccine ganciclovir patient stage I , II , III malignant mesothelioma . II . Determine maximum tolerate dose dose limit toxicity vaccine patient . III . Determine immunologic response treatment regimen patient . IV . Determine intrapleural pharmakokinetics ganciclovir patient . OUTLINE : This dose escalation study PA-1-STK modify ovarian carcinoma vaccine . Patients receive PA-1-STK modify ovarian carcinoma vaccine intrapleurally day 1 follow ganciclovir IV 1 hour 7 day begin day 1 . Patients first 2 cohort receive 1 course treatment . In subsequent cohort , treatment repeat every 3 week total 3 course absence disease progression unacceptable toxicity . Cohorts 3 patient receive escalate dos PA-1-STK modify ovarian carcinoma vaccine maximum tolerate dose determine . PROJECTED ACCRUAL : A total 3-16 patient accrue study .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage I , II , III malignant mesothelioma Must adequate pleural space place chest tube catheter PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Hematocrit great 30 % WBC great 4,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin normal SGOT alkaline phosphatase less 1.5 time normal Renal : Creatinine le 1.5 mg/dL Creatinine clearance great 50 mL/min Cardiovascular : No significant history heart disease No frequent angina No myocardial infarction within past 6 month No congestive heart failure require daily treatment Pulmonary : No evidence moderate severe pulmonary disease ( i.e. , FEV1 le 40 % predict ) Other : No prior malignancy except squamous basal cell carcinoma skin No patient childbearing potential PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior chemotherapy Endocrine therapy : No concurrent steroid treatment Radiotherapy : At least 6 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>stage IA malignant mesothelioma</keyword>
	<keyword>stage IB malignant mesothelioma</keyword>
	<keyword>stage II malignant mesothelioma</keyword>
	<keyword>stage III malignant mesothelioma</keyword>
</DOC>